Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome-positive (Ph plus ) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

Stock, W; Martinelli, G; Stelljes, M; DeAngelo, DJ; Gokbuget, N; Advani, AS

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索